Losartan therapy for cardiac disease in paediatricMarfan syndrome

Lisa J Ewans; Phillip Roberts; Lesley Adès

doi:10.1111/jpc.12823

Losartan therapy for cardiac disease in paediatricMarfan syndrome

J Paediatr Child Health. 2015 Sep;51(9):927-31. doi: 10.1111/jpc.12823.

Authors

Lisa J Ewans¹, Phillip Roberts², Lesley Adès¹

Affiliations

¹ Clinical Genetics, The Children's Hospital at Westmead, Sydney, New South Wales, Australia.
² Paediatric Cardiology, The Children's Hospital at Westmead, Sydney, New South Wales, Australia.

PMID: 26333075
DOI: 10.1111/jpc.12823

Abstract

A case of severe early-onset Marfan syndrome (MFS) led us to ask the question: 'Should an ARB, particularly losartan [intervention], compared with beta blockade alone [comparison], be commenced in all paediatric MFS patients [patient] with aortic root dilatation [outcome]?' The current literature was critically appraised to address this question.

Keywords: cardiology; genetics; pharmacology.

Publication types

Case Reports

MeSH terms

Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Aorta / abnormalities
Dilatation, Pathologic
Female
Heart Defects, Congenital / drug therapy*
Humans
Infant, Newborn
Losartan / therapeutic use*
Marfan Syndrome / drug therapy*

Substances

Angiotensin II Type 1 Receptor Blockers
Losartan